Morgan (on behalf of Vikram)'s questions to Axsome Therapeutics Inc (AXSM) leadership • Q3 2024
Question
Morgan, on behalf of Vikram, inquired about the timeline and expected sales lift from the planned Auvelity sales force expansion, and the strategic driver behind it, questioning if it was for Major Depressive Disorder (MDD) or in preparation for a potential Alzheimer's Disease Agitation (ADA) launch.
Answer
Ari Maizel, Chief Commercial Officer, stated the expansion is expected to be completed in Q1 2025, with an anticipated sales lift building throughout the year, similar to the previous expansion. Maizel clarified the expansion is primarily to capitalize on MDD market access wins and primary care growth, but acknowledged potential future synergies for an ADA launch.